Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 806

1.

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.

Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.

PMID:
23299930
2.

MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.

Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y.

PLoS One. 2014 Dec 22;9(12):e115565. doi: 10.1371/journal.pone.0115565. eCollection 2014.

3.

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.

Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.

Cancer Lett. 2014 Dec 1;355(1):96-105. doi: 10.1016/j.canlet.2014.09.011. Epub 2014 Sep 11.

PMID:
25218350
4.

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.

Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.

Cell Signal. 2014 May;26(5):1030-9. doi: 10.1016/j.cellsig.2014.01.026. Epub 2014 Jan 29.

PMID:
24486412
5.

SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.

Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.

Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18.

6.

Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.

Liu LP, Ho RL, Chen GG, Lai PB.

Clin Cancer Res. 2012 Oct 15;18(20):5662-71. doi: 10.1158/1078-0432.CCR-12-0552. Epub 2012 Aug 28.

7.

Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.

Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.

Hepatology. 2015 Aug;62(2):534-45. doi: 10.1002/hep.27859. Epub 2015 Jun 3.

PMID:
25902734
8.

EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.

Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P.

Cell Cycle. 2008 Aug;7(15):2409-17. Epub 2008 Jun 9.

9.

Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.

Wang J, Ma Y, Jiang H, Zhu H, Liu L, Sun B, Pan S, Krissansen GW, Sun X.

J Hepatol. 2011 Aug;55(2):359-68. doi: 10.1016/j.jhep.2010.10.043. Epub 2010 Dec 17.

PMID:
21168458
10.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

11.
12.

Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.

Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.

PLoS One. 2013 Jun 20;8(6):e66589. doi: 10.1371/journal.pone.0066589. Print 2013.

13.

Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.

Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH.

Surgery. 2014 Aug;156(2):270-9. doi: 10.1016/j.surg.2014.04.055. Epub 2014 Jun 19.

PMID:
24953273
14.

Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.

Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.

Int J Oncol. 2014 Jul;45(1):177-88. doi: 10.3892/ijo.2014.2423. Epub 2014 May 6.

PMID:
24807012
15.

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.

Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.

Biomaterials. 2015 Oct;67:194-203. doi: 10.1016/j.biomaterials.2015.07.035. Epub 2015 Jul 21.

PMID:
26218745
16.

Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.

Xu M, Zheng YL, Xie XY, Liang JY, Pan FS, Zheng SG, Lü MD.

DNA Cell Biol. 2014 May;33(5):275-81. doi: 10.1089/dna.2013.2184. Epub 2014 Mar 10.

PMID:
24611881
17.

Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.

Kim Y, Jang M, Lim S, Won H, Yoon KS, Park JH, Kim HJ, Kim BH, Park WS, Ha J, Kim SS.

Hepatology. 2011 Nov;54(5):1661-78. doi: 10.1002/hep.24539.

PMID:
21748762
18.

In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.

Liu H, Liang Y, Wang L, Tian L, Song R, Han T, Pan S, Liu L.

PLoS One. 2012;7(10):e48075. doi: 10.1371/journal.pone.0048075. Epub 2012 Oct 31.

19.

Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.

Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.

Hepatology. 2014 Jan;59(1):190-201. doi: 10.1002/hep.26640. Epub 2013 Dec 9.

PMID:
23908138
20.

Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.

Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, Huang GL, Wang W, Zheng SG, Lü MD.

Acta Radiol. 2013 Mar 1;54(2):199-204. doi: 10.1258/ar.2012.120249. Epub 2012 Nov 21.

PMID:
23171528
Items per page

Supplemental Content

Write to the Help Desk